Quality cell lines, by design.

Off-the-shelf iPSC lines manufactured under GMP from start to finish.

About Us

 

GMP-compliant iPSC Lines

Our team of iPSC experts has spent more than a decade rigorously developing an iPSC platform. Manufactured in compliance with GMP, our iPSC lines provide therapeutic developers with high-quality, reliable starting material for manufacturing cell therapies, accelerating GMP reprogramming development timelines by 12 months and cutting cell line development costs by up to 60 per cent.
Our Platform

Position your cell therapy for success with our GMP iPSC lines

Graphic

GMP-compliant iPSC lines

GMP manufacturing throughout the entire process, with the end in mind. All reagents are GMP with full traceability.
We enhance regulatory compliance.

Graphic

Access to Experts

Access our iPSC experts during your evaluation of our cell lines to support cell line selection.
We enhance clinical translation.

Graphic

Genetic Safety Data

Evaluation of culture-induced abnormalities and genetic stability at high passage number.
We enhance drug product safety.

Graphic

Transparent and Flexible Terms

Visibility on licensing terms during the evaluation phase and flexibility on structuring the license.
We enhance your business planning.

Graphic

Submission Ready

Drug master file that can be cross-referenced in regulatory submissions to ensure your CMC data package is complete.
We enhance your regulatory submission.

 

iPSC Lines Tailored to Your Needs

Accelerate your time to GMP and to the clinic with the right line, under the right terms. LineaBio offers cell therapy developers with flexibility for both unmodified and gene-edited iPSC lines, providing either non-exclusive or exclusive licenses using a customized pricing model, supported by drug master files.

Our Products

News


LineaBio submits Drug Master File for Linea 1 GMP iPSC line to U.S. Food and Drug Administration
November 20, 2024 (Toronto, Ontario) – LineaBio announced it has submitted a Type II DMF to the FDA for its flagship iPSC line, Linea 1. [...]

Read More... from LineaBio submits Drug Master File for Linea 1 GMP iPSC line to U.S. Food and Drug Administration


LineaBio launches off-the-shelf GMP iPSC lines to accelerate iPSC-based cell therapies
July 30, 2024 – LineaBio, a cell line company, today announced the launch of its off-the-shelf induced pluripotent stem cell (iPSC) lines catalogue. [...]

Read More... from LineaBio launches off-the-shelf GMP iPSC lines to accelerate iPSC-based cell therapies